• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

在无心血管疾病史的 2 型糖尿病患者中,托格列净的长期作用对动脉粥样硬化进展和主要临床参数的影响:UTOPIA 试验的 2 年延长研究。

Tofogliflozin long-term effects on atherosclerosis progression and major clinical parameters in patients with type 2 diabetes mellitus lacking a history of cardiovascular disease: a 2-year extension study of the UTOPIA trial.

机构信息

Department of Metabolic Medicine, Osaka University Graduate School of Medicine, 2-2, Yamadaoka, Suita, Osaka, 565-0871, Japan.

Department of Metabolism and Atherosclerosis, Osaka University Graduate School of Medicine, 2-2, Yamadaoka, Suita, Osaka, 565-0871, Japan.

出版信息

Cardiovasc Diabetol. 2023 Jun 22;22(1):143. doi: 10.1186/s12933-023-01879-4.

DOI:10.1186/s12933-023-01879-4
PMID:37349722
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10286339/
Abstract

BACKGROUND

This study aimed to assess the long-term effects of tofogliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, on atherosclerosis progression and major clinical parameters in patients with type 2 diabetes lacking an apparent history of cardiovascular disease.

METHODS

This was a prospective observational 2-year extension study of the "Using TOfogliflozin for Possible better Intervention against Atherosclerosis for type 2 diabetes patients (UTOPIA)" trial, a 2-year randomized intervention study. The primary endpoints represented changes in the carotid intima-media thickness (IMT). Secondary endpoints included brachial-ankle pulse wave velocity (baPWV) and biomarkers for glucose metabolism, lipid metabolism, renal function, and cardiovascular risks.

RESULTS

The mean IMT of the common carotid artery (IMT-CCA) significantly decreased in both the tofogliflozin (- 0.067 mm, standard error 0.009, p < 0.001) and conventional treatment groups (- 0.080 mm, SE 0.009, p < 0.001) throughout the follow-up period; however, no significant intergroup differences in the changes (0.013 mm, 95% confidence interval (CI) - 0.012 to 0.037, p = 0.32) were observed in a mixed-effects model for repeated measures. baPWV significantly increased in the conventional treatment group (82.7 ± 210.3 cm/s, p = 0.008) but not in the tofogliflozin group (- 17.5 ± 221.3 cm/s, p = 0.54), resulting in a significant intergroup difference in changes (- 100.2 cm/s, 95% CI - 182.8 to - 17.5, p = 0.018). Compared to the conventional treatment group, tofogliflozin significantly improved the hemoglobin A1c and high-density lipoprotein cholesterol levels, body mass index, abdominal circumference, and systolic blood pressure. The frequencies of total and serious adverse events did not vary significantly between the groups.

CONCLUSIONS

Tofogliflozin was not associated with improved inhibition of carotid wall thickening but exerted long-term positive effects on various cardiovascular risk factors and baPWV while showing a good safety profile.

摘要

背景

本研究旨在评估钠-葡萄糖共转运蛋白 2(SGLT2)抑制剂托格列净在无明显心血管疾病史的 2 型糖尿病患者中的长期疗效,评估其对动脉粥样硬化进展和主要临床参数的影响。

方法

这是一项为期 2 年的“使用托格列净治疗 2 型糖尿病患者以可能更好地干预动脉粥样硬化(UTOPIA)”试验的前瞻性观察性 2 年扩展研究,该试验为一项为期 2 年的随机干预研究。主要终点是颈动脉内膜中层厚度(IMT)的变化。次要终点包括臂踝脉搏波速度(baPWV)和葡萄糖代谢、脂质代谢、肾功能和心血管风险的生物标志物。

结果

在整个随访期间,颈动脉(CCA-IMT)的平均 IMT 在托格列净组(-0.067mm,标准误差 0.009,p<0.001)和常规治疗组(-0.080mm,SE 0.009,p<0.001)均显著降低;然而,在混合效应重复测量模型中,两组间的变化无显著差异(0.013mm,95%置信区间(CI)-0.012 至 0.037,p=0.32)。baPWV 在常规治疗组显著增加(82.7±210.3cm/s,p=0.008),而在托格列净组无显著增加(-17.5±221.3cm/s,p=0.54),两组间的变化存在显著差异(-100.2cm/s,95%CI-182.8 至-17.5,p=0.018)。与常规治疗组相比,托格列净显著改善了血红蛋白 A1c 和高密度脂蛋白胆固醇水平、体重指数、腰围和收缩压。两组的总不良事件和严重不良事件发生率无显著差异。

结论

托格列净与改善颈动脉壁增厚的抑制作用无关,但长期对各种心血管危险因素和 baPWV 有积极影响,同时具有良好的安全性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b784/10286339/cf1fcd1e9dcb/12933_2023_1879_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b784/10286339/cf1fcd1e9dcb/12933_2023_1879_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b784/10286339/cf1fcd1e9dcb/12933_2023_1879_Fig1_HTML.jpg

相似文献

1
Tofogliflozin long-term effects on atherosclerosis progression and major clinical parameters in patients with type 2 diabetes mellitus lacking a history of cardiovascular disease: a 2-year extension study of the UTOPIA trial.在无心血管疾病史的 2 型糖尿病患者中,托格列净的长期作用对动脉粥样硬化进展和主要临床参数的影响:UTOPIA 试验的 2 年延长研究。
Cardiovasc Diabetol. 2023 Jun 22;22(1):143. doi: 10.1186/s12933-023-01879-4.
2
Tofogliflozin does not delay progression of carotid atherosclerosis in patients with type 2 diabetes: a prospective, randomized, open-label, parallel-group comparative study.托格列净不会延缓 2 型糖尿病患者颈动脉粥样硬化的进展:一项前瞻性、随机、开放标签、平行组对照研究。
Cardiovasc Diabetol. 2020 Jul 9;19(1):110. doi: 10.1186/s12933-020-01079-4.
3
Effect of tofogliflozin on arterial stiffness in patients with type 2 diabetes: prespecified sub-analysis of the prospective, randomized, open-label, parallel-group comparative UTOPIA trial.在 2 型糖尿病患者中,托格列净对动脉僵硬度的影响:前瞻性、随机、开放标签、平行组比较 UTOPIA 试验的预设亚分析。
Cardiovasc Diabetol. 2021 Jan 4;20(1):4. doi: 10.1186/s12933-020-01206-1.
4
Evaluation of the effect of tofogliflozin on the tissue characteristics of the carotid wall-a sub-analysis of the UTOPIA trial.评价托格列净对颈动脉壁组织特征的影响——UTOPIA 试验的一项亚分析。
Cardiovasc Diabetol. 2022 Feb 5;21(1):19. doi: 10.1186/s12933-022-01451-6.
5
Cardio-ankle vascular index is more closely associated than brachial-ankle pulse wave velocity with arterial damage and risk of cardiovascular disease in patients with diabetes.心血管踝肱指数与肱踝脉搏波速度相比,与糖尿病患者的动脉损伤和心血管疾病风险的相关性更密切。
BMC Cardiovasc Disord. 2022 Aug 9;22(1):365. doi: 10.1186/s12872-022-02800-9.
6
Clinical utility of brachial-ankle pulse wave velocity in the prediction of cardiovascular events in diabetic patients.肱踝脉搏波速度在预测糖尿病患者心血管事件中的临床应用价值
Cardiovasc Diabetol. 2014 Sep 5;13:128. doi: 10.1186/s12933-014-0128-5.
7
Rationale, Design, and Baseline Characteristics of the Utopia Trial for Preventing Diabetic Atherosclerosis Using an SGLT2 Inhibitor: A Prospective, Randomized, Open-Label, Parallel-Group Comparative Study.使用SGLT2抑制剂预防糖尿病动脉粥样硬化的乌托邦试验的原理、设计和基线特征:一项前瞻性、随机、开放标签、平行组比较研究。
Diabetes Ther. 2017 Oct;8(5):999-1013. doi: 10.1007/s13300-017-0292-1. Epub 2017 Sep 1.
8
Rationale and design of a multicenter randomized controlled study to evaluate the preventive effect of ipragliflozin on carotid atherosclerosis: the PROTECT study.一项评估依帕列净对颈动脉粥样硬化预防作用的多中心随机对照研究的原理与设计:PROTECT研究
Cardiovasc Diabetol. 2016 Sep 13;15(1):133. doi: 10.1186/s12933-016-0449-7.
9
Association between circulating leukocyte subtype counts and carotid intima-media thickness in Japanese subjects with type 2 diabetes.日本2型糖尿病患者循环白细胞亚型计数与颈动脉内膜中层厚度之间的关联。
Cardiovasc Diabetol. 2013 Dec 27;12:177. doi: 10.1186/1475-2840-12-177.
10
Carotid Intima-Media Thickness, Ankle-Arm Index, and Inflammation Profile in Mexican Patients with Early and Late Onset Type 2 Diabetes.墨西哥早发和晚发2型糖尿病患者的颈动脉内膜中层厚度、踝臂指数及炎症指标
Rev Invest Clin. 2015 Jul-Aug;67(4):240-9.

引用本文的文献

1
SGLT2 Inhibitors: From Structure-Effect Relationship to Pharmacological Response.钠-葡萄糖协同转运蛋白2(SGLT2)抑制剂:从构效关系到药理反应
Int J Mol Sci. 2025 Jul 19;26(14):6937. doi: 10.3390/ijms26146937.
2
Evaluating the Safety and Efficacy of SGLT-2 Inhibitors on Reducing Cardiovascular and Renal Mortality, Morbidity and Inflammatory Outcomes in Various Patient Populations: A Systematic Review and Meta-Analysis of 92 920 Patients.评估钠-葡萄糖协同转运蛋白2(SGLT-2)抑制剂在降低各类患者群体心血管和肾脏死亡率、发病率及炎症结局方面的安全性和有效性:一项对92920例患者的系统评价和荟萃分析
Clin Med Insights Cardiol. 2025 Jun 30;19:11795468251347777. doi: 10.1177/11795468251347777. eCollection 2025.
3

本文引用的文献

1
Efficacy of Sodium-Glucose Cotransporter 2 Inhibitors on Outcomes After Catheter Ablation for Atrial Fibrillation.钠-葡萄糖共转运蛋白 2 抑制剂对导管消融治疗心房颤动后结局的影响。
JACC Clin Electrophysiol. 2022 Nov;8(11):1393-1404. doi: 10.1016/j.jacep.2022.08.004. Epub 2022 Oct 26.
2
Tofogliflozin, a sodium-glucose cotransporter 2 inhibitor, improves pulmonary vascular remodeling due to left heart disease in mice.托格列净,一种钠-葡萄糖共转运蛋白 2 抑制剂,可改善因左心疾病导致的小鼠肺血管重构。
J Cardiol. 2023 Apr;81(4):347-355. doi: 10.1016/j.jjcc.2022.10.003. Epub 2022 Oct 14.
3
Comparison of cardiovascular outcomes between SGLT2 inhibitors in diabetes mellitus.
The Potential Impact of SGLT2-I in Diabetic Foot Prevention: Promising Pathophysiologic Implications, State of the Art, and Future Perspectives-A Narrative Review.
钠-葡萄糖协同转运蛋白 2 抑制剂在糖尿病足预防中的潜在影响:有前景的病理生理意义、现状和未来展望——一篇叙述性综述。
Medicina (Kaunas). 2024 Nov 1;60(11):1796. doi: 10.3390/medicina60111796.
4
Effects of 6-month administration of tofogliflozin on cardiac function in elderly patients with heart failure with preserved ejection fraction: A retrospective study of a patient cohort.托格列净治疗 6 个月对射血分数保留的心力衰竭老年患者心功能的影响:一项患者队列的回顾性研究。
Medicine (Baltimore). 2024 Aug 9;103(32):e38948. doi: 10.1097/MD.0000000000038948.
5
Novel Therapeutics for Type 2 Diabetes Mellitus-A Look at the Past Decade and a Glimpse into the Future.2型糖尿病的新型疗法——回顾过去十年并展望未来
Biomedicines. 2024 Jun 21;12(7):1386. doi: 10.3390/biomedicines12071386.
6
Longitudinal assessment of coronary plaque regression related to sodium-glucose cotransporter-2 inhibitor using coronary computed tomography angiography.利用冠状动脉计算机断层扫描血管造影评估钠-葡萄糖共转运蛋白 2 抑制剂相关的冠状动脉斑块消退情况:一项纵向研究。
Cardiovasc Diabetol. 2024 Jul 22;23(1):267. doi: 10.1186/s12933-024-02368-y.
比较 SGLT2 抑制剂在糖尿病患者中的心血管结局。
Cardiovasc Diabetol. 2022 May 18;21(1):67. doi: 10.1186/s12933-022-01508-6.
4
Evaluation of the effect of tofogliflozin on the tissue characteristics of the carotid wall-a sub-analysis of the UTOPIA trial.评价托格列净对颈动脉壁组织特征的影响——UTOPIA 试验的一项亚分析。
Cardiovasc Diabetol. 2022 Feb 5;21(1):19. doi: 10.1186/s12933-022-01451-6.
5
The Influence of Tofogliflozin on Treatment-Related Quality of Life in Patients with Type 2 Diabetes Mellitus.托格列净对2型糖尿病患者治疗相关生活质量的影响
Diabetes Ther. 2021 Sep;12(9):2499-2515. doi: 10.1007/s13300-021-01125-8. Epub 2021 Aug 6.
6
Effect of tofogliflozin on arterial stiffness in patients with type 2 diabetes: prespecified sub-analysis of the prospective, randomized, open-label, parallel-group comparative UTOPIA trial.在 2 型糖尿病患者中,托格列净对动脉僵硬度的影响:前瞻性、随机、开放标签、平行组比较 UTOPIA 试验的预设亚分析。
Cardiovasc Diabetol. 2021 Jan 4;20(1):4. doi: 10.1186/s12933-020-01206-1.
7
Effects of luseogliflozin on arterial properties in patients with type 2 diabetes mellitus: The multicenter, exploratory LUSCAR study.利格列汀对 2 型糖尿病患者动脉功能的影响:多中心、探索性的 LUSCAR 研究。
J Clin Hypertens (Greenwich). 2020 Sep;22(9):1585-1593. doi: 10.1111/jch.13988. Epub 2020 Aug 18.
8
Tofogliflozin does not delay progression of carotid atherosclerosis in patients with type 2 diabetes: a prospective, randomized, open-label, parallel-group comparative study.托格列净不会延缓 2 型糖尿病患者颈动脉粥样硬化的进展:一项前瞻性、随机、开放标签、平行组对照研究。
Cardiovasc Diabetol. 2020 Jul 9;19(1):110. doi: 10.1186/s12933-020-01079-4.
9
Renal, Cardiovascular, and Safety Outcomes of Canagliflozin by Baseline Kidney Function: A Secondary Analysis of the CREDENCE Randomized Trial.基于基线肾功能的坎格列净的肾脏、心血管和安全性结局:CREDENCE 随机试验的二次分析。
J Am Soc Nephrol. 2020 May;31(5):1128-1139. doi: 10.1681/ASN.2019111168.
10
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy.卡格列净与 2 型糖尿病和肾病患者的肾脏结局。
N Engl J Med. 2019 Jun 13;380(24):2295-2306. doi: 10.1056/NEJMoa1811744. Epub 2019 Apr 14.